1. Could an antianginal metabolic agent have an impact on prognosis in ischemic patients? Beneficial effects of trimetazidine in patients with acute myocardial infarction Kim JS et al. Clin Res Cardiol. DOI 10.1007/s00392-013-0611-0.

2. Impact of trimetazidine on prognosis Methods  Among the 13 000 AMI patients involved in the large-scale, prospective, observational Korean Acute Myocardial Infarction Registry (KAMIR), those receiving trimetazidine were included in the present analysis.  Two groups: patients treated with trimetazidine (either the 20 mg tablet or the 35 mg modified- release tablet) during their in-hospital management period and patients who were not.  A propensity score analysis was performed to equilibrate the 2 groups.  75% received  -blockers, 90% statins, and 90% ACE inhibitors/ARBs.  Primary end points: all-cause death and major adverse cardiac events (MACE), which included all-cause death, recurrent myocardial infarction, repeat PCI for target lesion revascularization, and CABG. Kim JS et al. Clin Res Cardiol. DOI 10.1007/s00392-013-0611-0.

3. All results Impact of trimetazidine on prognosis Kim JS et al. Clin Res Cardiol. DOI 10.1007/s00392-013-0611-0. Trimetazidine

4. Results on MACE Impact of trimetazidine on prognosis One year Trimetazidine Control MACE: all-cause death, recurrent myocardial infarction, repeated PCI for target lesion revascularization, and CABG. Kim JS et al. Clin Res Cardiol. DOI 10.1007/s00392-013-0611-0.

5. Results on all-cause death Impact of trimetazidine on prognosis One year Trimetazidine Control Trimetazidine Control Kim JS et al. Clin Res Cardiol. DOI 10.1007/s00392-013-0611-0.

6. Impact of trimetazidine on prognosis Discussion Kim JS et al. Clin Res Cardiol. DOI 10.1007/s00392-013-0611-0. TMZ = Trimetazidine

7. Conclusion Several previous clinical studies have already shown that trimetazidine may improve prognosis in heart failure and post-MI patients. 1-3 This new study demonstrates that patients who receive trimetazidine seem to live longer after an MI. This cardiac protection against ischemia could be linked to the 33% energy increase provided by trimetazidine in cardiomyocytes. 1. Gao D et al. Heart. 97:278-286. 2. Fragasso G et al. Int J Cardiol. 163:320-325. 3. Iyengar SS et al. (METRO). Am J Cardiovasc Drugs. 9:293-297.